Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (HK:2252)
:2252
Want to see HK:2252 full AI Analyst Report?
2252 Stock Chart & Stats
HK$34.14
-HK$0.03(-0.33%)
At close: 4:00 PM EST
HK$34.14
-HK$0.03(-0.33%)
Day’s Range― - ―
52-Week RangeHK$14.58 - HK$35.34
Previous CloseN/A
Volume4.35M
Average Volume (3M)5.91M
Market Cap
HK$26.29B
Enterprise ValueHK$22.21B
Total Cash (Recent Filing)HK$640.42M
Total Debt (Recent Filing)HK$426.37M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Sep 02, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding1,030,720,600
10 Day Avg. Volume5,228,361
30 Day Avg. Volume5,906,894
Financial Highlights & Ratios
PEG Ratio1.40
Price to Book (P/B)54.27
Price to Sales (P/S)40.46
P/FCF Ratio-574.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$39.27Price Target Upside15.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$1.13B
Bulls Say, Bears Say
Bulls Say
Revenue AccelerationA sustained revenue acceleration (+~61% in 2025) signals improving commercial traction for surgical robotic platforms. If durable, this growth supports scale advantages, strengthens hospital adoption, and underpins future margin expansion and recurring instrument/service revenue over the medium term.
Positive Gross MarginA positive gross margin (~29%) indicates underlying unit economics for hardware and consumables. This margin level provides a foundation to move toward operating profitability as fixed costs are absorbed by higher volume and recurring attach rates for instruments and services.
Improved LeverageDebt-to-equity falling to about 1.0 from ~2.5 materially reduces solvency risk and interest burden. Improved leverage enhances financial flexibility to fund R&D and commercialization without immediate refinancing pressure, supporting a steadier multi-quarter execution runway.
Bears Say
Sustained Net LossesA ~-45% net margin in 2025 shows the business remains loss-making at scale, eroding retained capital and requiring external funding. Persistent operating losses constrain reinvestment, limit free-cash generation, and delay durable path to self-funded growth until operating margins materially improve.
Negative Cash GenerationRepeated negative operating and free cash flow mean the company cannot yet self-fund expansion. Volatile FCF and continued cash burn create reliance on external financing, which can dilute shareholders or limit long-term investment flexibility if funding conditions tighten.
Eroding Equity And ReturnsDeclining equity and an ROE near -59% indicate losses are eroding the capital base, raising solvency and partner-risk concerns. Weak returns reduce the firm's buffer against shocks and may impair ability to form large hospital partnerships or pursue capital-intensive rollouts without further fundraising.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H News
2252 FAQ
What was Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price range in the past 12 months?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H lowest stock price was HK$14.58 and its highest was HK$35.34 in the past 12 months.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s market cap is HK$26.29B.
When is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 92 days.
How were Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s earnings last quarter?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.161 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.161.
Is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H pay dividends?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H does not currently pay dividends.
What is Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s EPS estimate is -0.01.
How many shares outstanding does Shanghai MicroPort MedBot (Group) Co., Ltd. Class H have?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H has 1,030,720,600 shares outstanding.
What happened to Shanghai MicroPort MedBot (Group) Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H reported an EPS of -HK$0.161 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.136%.
Which hedge fund is a major shareholder of Shanghai MicroPort MedBot (Group) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2252
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$39.27 (15.02% Upside)
HK$39.27 (15.02% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
-52.78%
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and automated needle targeting robotics systems for percutaneous lung biopsy and percutaneous nephrolithotomy. Shanghai Microport Medbot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai Microport Medbot (Group) Co., Ltd. operates as a subsidiary of MicroPort Scientific Corporation.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) Earnings & Revenues
2252 Stock 12 Month Forecast
Average Price Target
HK$39.27
▲(15.02% Upside)
Technical Analysis
MicroPort Scientific
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---